Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE
NCT04270682Phase 3Completed
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Jan 2020
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of chenodeoxycholic acid in cerebrotendinous xanthomatosis (CTX), sponsored by Mirum Pharmaceuticals, Inc.. Started Jan 2020; status: completed.
02
Drugs
chenodeoxycholic acid
03
Conditions
cerebrotendinous xanthomatosis (CTX)
Beyond the preview
Go deeper on NCT04270682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04270682.